Reta CAG peptide blends retatrutide and cagrilintide in unregulated research vials. Learn how both drugs work, what trials show, and their legal status.
Reta CAG peptide is an informal label for a research-only blend of retatrutide ("Reta") and cagrilintide ("CAG"), two investigational weight-management drugs that are not FDA-approved for human use. Retatrutide is Eli Lilly's triple GIP/GLP-1/glucagon receptor agonist, and cagrilintide is Novo Nordisk's amylin analog. No drugmaker has published human trial results on the two compounds combined, so any vial sold as "Reta CAG" is an unregulated research chemical rather than a finished medicine.
What "Reta CAG" Means in the Peptide Market
In vendor listings and forum threads, "Reta" is shorthand for retatrutide and "CAG" is shorthand for cagrilintide. Some sellers combine both powders in a single vial and market the result as a next-generation metabolic stack.
That shorthand causes real confusion. Most people asking what is reta peptide are asking about retatrutide on its own, not a two-drug blend, and the two are not interchangeable.
Cagrilintide is genuinely studied as part of a combination therapy, but with semaglutide under the name CagriSema. That pairing belongs to Novo Nordisk, not to retatrutide.
How Retatrutide and Cagrilintide Work
Both compounds mimic hormones the gut and pancreas already release, but they act on different receptors. That difference shapes both the side effect profile and the size of the effect reported in clinical trials.
| Feature | Retatrutide ("Reta") | Cagrilintide ("CAG") |
|---|---|---|
| Developer | Eli Lilly | Novo Nordisk |
| Receptor targets | GIP, GLP-1, and glucagon receptors | Amylin and calcitonin receptors |
| Administration | Once-weekly subcutaneous injection | Once-weekly subcutaneous injection |
| Furthest trial stage | Phase 3 (TRIUMPH program) | Phase 3 (as part of CagriSema) |
| FDA approval status | Not approved for any use | Not approved as a standalone drug |
| Weight loss reported in trials | Up to about 24% at 48 weeks (Phase 2) | About 22.7% at 68 weeks when paired with semaglutide |
Retatrutide: Three Receptors at Once
Retatrutide activates GLP-1, GIP, and glucagon receptors simultaneously. The glucagon component is unusual and is thought to raise energy expenditure, which is one reason researchers monitor liver and heart markers closely in its trials.
Cagrilintide: An Amylin Analog
Cagrilintide copies amylin, a hormone released alongside insulin that slows stomach emptying and signals fullness. Amylin analogs are already used in diabetes and weight management, but cagrilintide itself remains experimental.
What the Clinical Trial Data Actually Show
Retatrutide's most-cited human data come from a Phase 2 trial published in 2023, in which participants on the highest weekly dose lost roughly 24% of their body weight over 48 weeks. Phase 3 trials are still running, so the final safety picture is not settled.
Cagrilintide's largest dataset comes from the CagriSema program, where it was tested alongside semaglutide rather than alone. In the REDEFINE 1 trial, that combination produced about 22.7% average weight loss at 68 weeks.
Anyone digging into reta peptide clinical trial results should note one large gap: every published study involves retatrutide by itself or cagrilintide paired with semaglutide. There is no human trial of retatrutide plus cagrilintide, and no dose for that combination has ever been established.
Reported Benefits and What Remains Unproven
Reported reta peptide benefits in the trial setting include substantial weight reduction, lower blood sugar, and improvement in some cardiovascular and liver markers. Those results come from specific doses given under medical supervision, with regular lab monitoring.
The list of unknowns is far longer than the list of proven benefits:
- Whether combining retatrutide and cagrilintide adds anything over either drug alone.
- What a safe or effective dose of the blend would be.
- How the side effects of the two compounds interact.
- Long-term effects on the thyroid, pancreas, gallbladder, and lean muscle mass.
Stacking With Other Research Peptides
Sellers sometimes bundle these compounds with growth-hormone peptides, and shoppers search for reta and tesa peptide combinations. Tesamorelin is a GHRH analog approved in the United States for HIV-associated lipodystrophy, but it has never been studied alongside a triple agonist.
Stacking two unapproved research chemicals multiplies the unknowns without adding evidence. No dosing schedule, interaction study, or monitoring protocol exists for these combinations.
Safety and Legal Status in the United States
Neither retatrutide nor cagrilintide is FDA-approved, and neither can lawfully be sold as a dietary supplement or a prescription drug. A vial labeled "research use only" is a laboratory chemical, not a medicine.
That answers the common question is reta peptide legal: buying it for personal injection sits outside the regulated supply chain, and sellers shipping it to consumers operate in a legal gray area. Possession rules vary by state, and importing unapproved drugs for personal use is not authorized.
Safety concerns with unregulated vials include dosing errors from self-reconstitution, contamination or wrong-peptide content, and injection-site reactions. Class-wide GLP-1 side effects such as nausea, vomiting, gallbladder disease, and pancreatitis have been reported with approved drugs in this family.
Anyone who is pregnant, has a medical condition, or takes other medications should talk with a healthcare professional before considering any compound in this class.
Buying "Reta CAG" Vials: What to Check
Shoppers often read reta peptide com reviews before ordering, and those reviews are worth treating as marketing until a lab report backs them up. If you are evaluating a vendor for laboratory work, verify:
- A certificate of analysis from an independent lab, not the seller's own.
- HPLC purity results plus mass spectrometry confirmation of identity.
- Lot numbers on the COA that match the vial you receive.
- Endotoxin and sterility testing, if the material is intended for any biological work.
- Cold-chain shipping and a clear statement that the product is not for human use.
Vendors that promise specific weight-loss results, quote human dosages, or describe their product as "pharmacy grade" are making claims they cannot support with data.
Bottom line: retatrutide and cagrilintide are promising investigational drugs on their own, and a combined "Reta CAG" product is an untested research compound with no human safety record.
Frequently Asked Questions
What is a reta CAG peptide?
Reta CAG peptide is a slang term for a vial containing both retatrutide and cagrilintide, two experimental weight-management drugs sold for research use. Neither drug is FDA-approved, and the combination has never been tested in humans. Products marketed under this name are unregulated chemicals, not medicines.
Is reta CAG peptide FDA-approved?
No. Retatrutide is still in Phase 3 trials, and cagrilintide is only being studied in combination with semaglutide as CagriSema. Neither compound has been approved by the FDA for weight loss or any other indication. Any seller claiming FDA approval for a reta CAG product is misrepresenting it.
Is it legal to buy reta CAG peptide in the US?
Because the FDA has not authorized retatrutide or cagrilintide for human use, they cannot legally be sold as drugs or dietary supplements. Research chemical suppliers operate in a gray area, and purchasing these vials for personal injection is not a regulated or approved practice. State rules and import policies vary, so check the specifics for your situation.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.